Investors & Media - BrainStorm Cell Therapeutics

News

Press Releases

Month Year

Investor Alerts

Mar 12, 2018

BrainStorm Announces Formation of Scientific Advisory Board and Appoints Neuroscientist Jerold Chun, M.D., Ph.D., to Chair

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today the formation of its Scientific Advisory Board...
Mar 8, 2018

BrainStorm Announces Operational Highlights and Financial Results for the Year Ended December 31, 2017

Conference Call and Webcast @ 8:30 a.m. Eastern Time Today

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announces financial results for the fourth quarter and...
Mar 5, 2018

BrainStorm to Host an Annual Financial Results Call and Provide a Corporate Update on Thursday, March 8

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will hold a conference call on Thursday, March 8 to discuss...
Feb 7, 2018

BrainStorm's NurOwn® Phase 2 ALS Clinical Trial and Biomarker Abstracts Accepted for Platform Presentations at the 70th Annual American Academy of Neurology Meeting in Los Angeles, California

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that two scientific posters describing...
Feb 6, 2018

BrainStorm Cell Therapeutics to Present at the BIO CEO & Investor Conference

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits, President & Chief...
Feb 5, 2018

BrainStorm Cell Therapeutics Appoints Senior Kite Executive, Anthony Polverino, Ph.D., to Board of Directors

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today the appointment of Anthony (Tony) Polverino,...
Jan 16, 2018

BrainStorm to Present at Precision Medicine World Conference 2018 Silicon Valley on January 22

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that Chaim Lebovits, President & CEO, and Dr....
Jan 3, 2018

BrainStorm Granted GMP Certification for a Marketing-Level Manufacturing of NurOwn®

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced it has received Good Manufacturing Practice...
Dec 29, 2017

Brainstorm Issues 2017 Letter to Shareholders

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today issued a Letter to Shareholders from its President and...
Dec 20, 2017

BrainStorm Cell Therapeutics to Present at the 10th Annual Biotech Showcase

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that Chaim Lebovits, Chief Executive Officer,...
Nov 29, 2017

BrainStorm's Abstracts on Phase 2 NurOwn® Biomarkers Accepted for Presentation at the International Symposium on ALS/MND in Boston

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced that two scientific posters describing...
Nov 9, 2017

New Peer Reviewed Publication Shows That BrainStorm's NurOwn® Has a Unique miRNA Signature

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced today that a study profiling NurOwn®'s unique miRNA...
Nov 2, 2017

BrainStorm Strengthens Executive Team: Appoints Eyal Rubin as Chief Financial Officer

Eyal Rubin, VP and Head of Corporate Treasury at Teva, is Third Senior Appointment at Brainstorm in 2017

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has appointed Eyal Rubin as Chief...
Oct 23, 2017

BrainStorm Expands Its Patent Portfolio to Include a New US Patent For Its NurOwn® Technology for Parkinson's Disease And ALS

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, announced that it has received Notice of Allowance from the...
Oct 17, 2017

BrainStorm Announces Third Quarter 2017 Financial Results

Conference Call with Management to Discuss Recent Corporate Progress at 8:30am Eastern Time Today

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced financial results for the third quarter ending...
Oct 16, 2017

BrainStorm Enrolls First Patients in Phase 3 Trial of NurOwn® in ALS

Trial supported by a $16M non-dilutive grant from CIRM

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI) today announced that the first patients have been enrolled in the Phase 3 clinical trial of NurOwn® for the treatment of amyotrophic lateral...
Oct 3, 2017

Brainstorm to Announce Third Quarter Financial Results And Provide Corporate Updates on Tuesday, October 17

Conference Call and Live Webcast at 8:30am Eastern Time

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce financial results for the three and nine months...
Sep 27, 2017

BrainStorm Cell Therapeutics to Present at the 2017 Disruptive Growth Company Showcase NYC Presented by SeeThruEquity and RHK Capital

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases announced today that it will be presenting at the 2017...
Aug 15, 2017

BrainStorm Announces Second Quarter 2017 Financial Results

Conference Call with Management to Discuss Recent Progress Wednesday, August 16, 2017 @ 8:30am Eastern Time

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced financial results for the second quarter ending June...
Aug 14, 2017

BrainStorm Announces Second Quarter 2017 Financial Results

Conference Call with Management to Discuss Recent Progress Wednesday, August 16, 2017 @ 8:30am Eastern Time

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced financial results for the second quarter ending June...
Aug 10, 2017

Brainstorm to Host Second-Quarter 2017 Earnings Teleconference and Provide Important Corporate Updates, on Wednesday, August 16

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, will announce financial results for the three and six months ended
- Photos 1
Aug 7, 2017

BrainStorm Supports Commitment to ALS Patient Community with Appointment of a Vice President of Patient Advocacy and Government Affairs

Mary Kay Turner brings 25+ years Biotech and Pharmaceutical Experience in Healthcare Advocacy and Policy; Prior Positions Include Head of Patient Advocacy and Communications at Mitsubishi Tanabe Pharma America and Head of State Government Affairs and Advocacy at Bristol-Myers Squibb Company

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today the appointment of Mary Kay Turner to the...
Jul 25, 2017

BrainStorm Announces Agreement with University of California Irvine Medical Center to Participate in Phase 3 Trial of NurOwn® in ALS

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has signed a definitive agreement with the
Jul 21, 2017

Brainstorm Awarded $16 Million Non-Dilutive Grant from CIRM in Support of Phase 3 Clinical Trial of NurOwn® in ALS

Brainstorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that the California Institute for Regenerative...
Jul 18, 2017

BrainStorm Announces Agreements with Mass. General Hospital and California Pacific Medical Center to Participate in Phase 3 Trial of NurOwn® in ALS

BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases, today announced that it has signed definitive agreements with...